New immunological results that support intralymphatic treatment with Diamyd® to be presented at the Immunology of Diabetes Society Congress

New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the positive clinical results shown in the DIAGNODE-1 trial. The results are presented this week at the international conference Immunology of Diabetes Society Congress 2018 in London."The results are encouraging and strengthen previously published immunological and clinical findings," says Rosaura Casas, Associate Professor of experimental pediatric immunology at Linköping University. “The most interesting finding is that intralymphatic treatment